Continued Prophylactic Treatment Of P. Marneffei Can Prevent Relapse

December 10, 1998

A large number of patients in Thailand who are infected with the Human Immunodeficiency Virus (HIV) have become ill from a previously very rare fungus called Penicillium Marneffei. Giving prophylactic itraconazole, an anti-fungal drug, to patients who have been treated for P. Marneffei, a potentially fatal fungal infection, can prevent a relapse of the infection. In a study of patients with HIV infection who responded to primary treatment for Penicillium Marneffei, researchers from the Johns Hopkins School of Public Health and Chiang Mai University in Thailand successfully administered itraconazole and prevented the recurrence of P. Marneffei. The study was published in the December 10, 1998 issue of The New England Journal of Medicine.

Kenrad Nelson, MD, professor, Epidemiology, Johns Hopkins School of Public Health said, "The relapse rate for P. Marneffei is about 50 percent in those patients without continued preventive treatment. We wanted to find a preventive treatment that was highly effective and well tolerated. We didn't expect the drug would work as well as it did." Dr. Nelson's team looked at 71 HIV- positive patients in Thailand who had received treatment for P. Marneffei. Half of them received itraconazole and half received a placebo. Twenty of those in the placebo group, more than half, had a relapse of P. Marneffei during the course of the study. None of those treated with itraconazole had a relapse. The median time to relapse was 24 weeks.

In northern Thailand, P. Marneffei is the third most common opportunistic infection in HIV patients. The infection causes weight loss, fever, anemia, and skin lesions. It has a 20% fatality rate even with appropriate treatment but is 100% fatal if not diagnosed and treated. Preventing relapse is highly preferable to treatment since some relapses can not be treated successfully. Dr. Nelson said, "This regimen should be the standard of care for patients with AIDS and P. Marneffei infection which is very common in AIDS patients in Thailand."

The study was supported by grants from Janssen Pharmaceutica, with support from the World Health Organization (WHO).
-end-


Johns Hopkins University Bloomberg School of Public Health

Related HIV Articles from Brightsurf:

BEAT-HIV Delaney collaboratory issues recommendations measuring persistent HIV reservoirs
Spearheaded by Wistar scientists, top worldwide HIV researchers from the BEAT-HIV Martin Delaney Collaboratory to Cure HIV-1 Infection by Combination Immunotherapy (BEAT-HIV Collaboratory) compiled the first comprehensive set of recommendations on how to best measure the size of persistent HIV reservoirs during cure-directed clinical studies.

The Lancet HIV: Study suggests a second patient has been cured of HIV
A study of the second HIV patient to undergo successful stem cell transplantation from donors with a HIV-resistant gene, finds that there was no active viral infection in the patient's blood 30 months after they stopped anti-retroviral therapy, according to a case report published in The Lancet HIV journal and presented at CROI (Conference on Retroviruses and Opportunistic Infections).

Children with HIV score below HIV-negative peers in cognitive, motor function tests
Children who acquired HIV in utero or during birth or breastfeeding did not perform as well as their peers who do not have HIV on tests measuring cognitive ability, motor function and attention, according to a report published online today in Clinical Infectious Diseases.

Efforts to end the HIV epidemic must not ignore people already living with HIV
Efforts to prevent new HIV transmissions in the US must be accompanied by addressing HIV-associated comorbidities to improve the health of people already living with HIV, NIH experts assert in the third of a series of JAMA commentaries.

The Lancet HIV: Severe anti-LGBT legislations associated with lower testing and awareness of HIV in African countries
This first systematic review to investigate HIV testing, treatment and viral suppression in men who have sex with men in Africa finds that among the most recent studies (conducted after 2011) only half of men have been tested for HIV in the past 12 months.

The Lancet HIV: Tenfold increase in number of adolescents on HIV treatment in South Africa since 2010, but many still untreated
A new study of more than 700,000 one to 19-year olds being treated for HIV infection suggests a ten-fold increase in the number of adolescents aged 15 to 19 receiving HIV treatment in South Africa, according to results published in The Lancet HIV journal.

Starting HIV treatment in ERs may be key to ending HIV spread worldwide
In a follow-up study conducted in South Africa, Johns Hopkins Medicine researchers say they have evidence that hospital emergency departments (EDs) worldwide may be key strategic settings for curbing the spread of HIV infections in hard-to-reach populations if the EDs jump-start treatment and case management as well as diagnosis of the disease.

NIH HIV experts prioritize research to achieve sustained ART-free HIV remission
Achieving sustained remission of HIV without life-long antiretroviral therapy (ART) is a top HIV research priority, according to a new commentary in JAMA by experts at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

The Lancet HIV: PrEP implementation is associated with a rapid decline in new HIV infections
Study from Australia is the first to evaluate a population-level roll-out of pre-exposure prophylaxis (PrEP) in men who have sex with men.

Researchers date 'hibernating' HIV strains, advancing BC's leadership in HIV cure research
Researchers have developed a novel way for dating 'hibernating' HIV strains, in an advancement for HIV cure research.

Read More: HIV News and HIV Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.